Making radium aimable.
Radium already treats cancer. We are engineering the protein that brings it to new targets.
Radium works. It just cannot be aimed.
Radium is a proven alpha emitter, but because chelation has not been therapeutically viable for radium, no systemically targeted radium exists. Xofigo is FDA-approved and Alpha DaRT is in the clinic, but Xofigo only goes where calcium goes and DaRT only goes where you implant it.
archR is a protein that holds radium.
Unlike chelation, archR is fundamentally designed for radium's unique chemistry.
The archR module fuses to a targeting protein as a single expressed construct, so one molecule carries both the payload and the precision.
Two paths.
Partners bring targeting molecules and we give those molecules the ability to hold radium. We also develop selected programs of our own.
Partner programs
You bring the targeting molecule. We give it the ability to hold radium.
Internal programs
We develop selected programs of our own, against targets we choose.
Team
Professor in Residence, Radiology, at UCSF. PI on first-in-human trials. 3x scientific co-founder.
Clinical and regulatory SME.
Professor of Biochemistry and Molecular Biology, Rutgers Robert Wood Johnson Medical School. Computational protein design.
Talk to us.
If you work on alpha emitters or on targets nothing has been able to drug, we want to hear from you.